PURPOSE: Determining the optimal starting dose of chemotherapy (CHT) presents a considerable challenge when using body-surface area (BSA)-based dosing, particularly in obese, elderly, or thin patients. We sought to document the range of approaches employed when administering CHT to these patients. METHODS: A questionnaire was developed by a panel of oncologists and mailed to all members of the Medical Oncology Group of Australia. RESULTS: From 315 oncologists, 188 responded (response rate 59.7%). BSA-based dosing is standard practice for 176 (97.2%) of the responding oncologists. In the adjuvant disease setting, 23 (12.7%) use ideal rather than actual body weight (BW) to calculate BSA, or choose whichever is less. When treating obese patients, only 6.1% of respondents routinely use actual BW. Of the remainder, 69.5% either cap the dose at 2 m(2) or use ideal BW. In underweight patients, 95% (n = 171) routinely calculate BSA using actual BW. Forty one respondents (22.7%) routinely reduce dose in the fit elderly. CONCLUSION: This analysis of BSA-based CHT dosing methods demonstrates significant variability in practice. Based on evidence from adjuvant studies showing that actual BSA-based dosing is desirable, a substantial number of Australian patients are being underdosed. Further education, together with ongoing research, is required to optimize individualized dosing for efficacy and tolerability.
PURPOSE: Determining the optimal starting dose of chemotherapy (CHT) presents a considerable challenge when using body-surface area (BSA)-based dosing, particularly in obese, elderly, or thin patients. We sought to document the range of approaches employed when administering CHT to these patients. METHODS: A questionnaire was developed by a panel of oncologists and mailed to all members of the Medical Oncology Group of Australia. RESULTS: From 315 oncologists, 188 responded (response rate 59.7%). BSA-based dosing is standard practice for 176 (97.2%) of the responding oncologists. In the adjuvant disease setting, 23 (12.7%) use ideal rather than actual body weight (BW) to calculate BSA, or choose whichever is less. When treating obesepatients, only 6.1% of respondents routinely use actual BW. Of the remainder, 69.5% either cap the dose at 2 m(2) or use ideal BW. In underweight patients, 95% (n = 171) routinely calculate BSA using actual BW. Forty one respondents (22.7%) routinely reduce dose in the fit elderly. CONCLUSION: This analysis of BSA-based CHT dosing methods demonstrates significant variability in practice. Based on evidence from adjuvant studies showing that actual BSA-based dosing is desirable, a substantial number of Australian patients are being underdosed. Further education, together with ongoing research, is required to optimize individualized dosing for efficacy and tolerability.
Authors: Sharyn D Baker; Jaap Verweij; Eric K Rowinsky; Ross C Donehower; Jan H M Schellens; Louise B Grochow; Alex Sparreboom Journal: J Natl Cancer Inst Date: 2002-12-18 Impact factor: 13.506
Authors: Ron H J Mathijssen; Jaap Verweij; Maja J A de Jonge; Kees Nooter; Gerrit Stoter; Alex Sparreboom Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544
Authors: G Berclaz; S Li; K N Price; A S Coates; M Castiglione-Gertsch; C-M Rudenstam; S B Holmberg; J Lindtner; D Erien; J Collins; R Snyder; B Thürlimann; M F Fey; C Mendiola; I Dudley Werner; E Simoncini; D Crivellari; R D Gelber; A Goldhirsch Journal: Ann Oncol Date: 2004-06 Impact factor: 32.976
Authors: Kathryn M Field; Suzanne Kosmider; Michael Jefford; Ross Jennens; Michael Green; Peter Gibbs Journal: J Oncol Pract Date: 2008-11 Impact factor: 3.840
Authors: J E Lau; C Weber; M Earl; L A Rybicki; K D Carlstrom; C M Wenzell; B T Hill; N S Majhail; M Kalaycio Journal: Bone Marrow Transplant Date: 2015-02-09 Impact factor: 5.483
Authors: Dan T Vogl; Tao Wang; Waleska S Pérez; Edward A Stadtmauer; Daniel F Heitjan; Hillard M Lazarus; Robert A Kyle; Ram Kamble; Daniel Weisdorf; Vivek Roy; John Gibson; Karen Ballen; Leona Holmberg; Asad Bashey; Philip L McCarthy; Cesar Freytes; Dipnarine Maharaj; Angelo Maiolino; David Vesole; Parameswaran Hari Journal: Biol Blood Marrow Transplant Date: 2011-05-11 Impact factor: 5.742